Today there is no single test or biomarker that can predict whether a particular person will develop Alzheimer´s disease and a definitive diagnosis is only possible after death – with postmortem analysis.
PredictAD is an EU funded research project which will study imaging biomarkers (MRI, PET FDG and PET PIB), electrical brain activity measurement and blood based markers (proteomics and metabolomics) and develop methods for how to combine data from different biomarkers.. Combining this multisource information may enable earlier diagnosis of Alzheimer’s disease, but may also provide crucial information used for differentiating between various forms of dementia and for assessing disease severity. It may also allow for improved detection of disease progression and treatment efficacy monitoring.
”The aim of PredictAD project is to develop an objective indicator to diagnose Alzheimer’s disease at the earliest stage possible. This may be possible by combining data from various data sources of patient monitoring, such as neuropsychological tests, medical imaging, electrical brain activity measurements, and analyzing protein and metabolomics levels of blood samples. Early diagnostics may play an important role in effective medical treatment of Alzheimer’s disease, especially in the future, as the next generation of more effective therapies become available for all patients,” says the Scientific Coordinator of the project, Dr. Jyrki Lötjönen from VTT.
“According to the latest estimates, the global prevalence of Alzheimer’s disease is predicted to quadruple to 106 million by 20501. Thus, there is a critical need for effective diagnostic tools to help in the early diagnosis of this debilitating disease," says Dr. Lennart Thurfjell, Head of Diagnostic Software, Medical Diagnostics at GE Healthcare.
At a later stage during this three-year project, a selected biomarker set will be used to develop an efficient and reliable software solution that can be used by a physician to assess the risk, to diagnose and to monitor the progress of Alzheimer’s disease in real clinical conditions using various patient data. The accuracy, usability and cost-effectiveness of the models and software will be clinically evaluated.
Currently, there is no curative treatment for Alzheimer's disease. If new drugs or prevention strategies were proven to be effective, an early diagnosis may enable doctors to provide medical care at an earlier stage, at a time when clinical diagnosis using only signs and symptoms of disease is challenging.
"PredictAD fits perfectly with GE Healthcare’s "Early Health" vision as it will help us gain important knowledge, not only about individual biomarkers, but also about how they may combine for early detection and therapy response monitoring. Improving our understanding of the role that different imaging and non-imaging biomarkers play during the disease process is the key as we strive to develop new diagnostic solutions for Alzheimer's disease," Dr. Thurfjell sums up.
Dementia causes long and oppressive suffering to patients and their relatives, and imposes enormous costs on society. Affecting more than 5 million people in Europe2, Alzheimer’s disease is the most common cause of dementia; it covers 50-70 % of all dementia cases2. Estimated costs of Alzheimer’s disease to European society are more than 55 billion € per annum3. As the proportion of elderly people of population is increasing these costs are becoming a real burden to the society. Therefore a major breakthrough in Alzheimer’s disease prevention and treatment is vital also in the economical sense.
With a consortium of top-level European research and industrial partners, the PredictAD project takes an important step towards an early approach to Alzheimer’s disease prediction and management. Public and private partners from 8 research,academic, industrial and medical organizations from four different European countries will form the research consortium. PredictAD consortium members are VTT Technical Research Centre of Finland, GE Healthcare (UK), Nextim Ltd. (Finland), University of Kuopio (Finland), Imperial College London (UK), Uppsala University (Sweden), University of Milan (Italy) and Rigshospitalet (Denmark).1 Forecasting the global burden of Alzheimer’s disease. Alzheimer’s and Dementia Vol. 3 pp. 186 – 191, July 2007.
About VTT Technical Research Centre of Finland
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE:GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries.Further information on VTT:
New way to look at cell membranes could change the way we study disease
19.11.2018 | University of Oxford
Controlling organ growth with light
19.11.2018 | European Molecular Biology Laboratory
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
19.11.2018 | Event News
09.11.2018 | Event News
06.11.2018 | Event News
19.11.2018 | Materials Sciences
19.11.2018 | Information Technology
19.11.2018 | Life Sciences